This year Richard Moriggl was selected for the "Große Zentraleuropäische Preis" for cancer research to mark his excellent scientific achievements in the field with the development of clinically relevant cancer models. His research proves to be of international relevance since many years. In the name of the entire board Univ.-Prof. Dr. Ehalt congratulated Richard Moriggl to his succesful research.
The LBG organised a special meeting for all Ludwig Boltzmann Institutes and Clusters, active in the area of medicine and life sciences as well as its related disciplines. The main purpose was to get to know each other’s research, to establish new cooperations under the roof of the LBG and to inform the medical community/public about the health related LBG activities. The common denominator of the participating institutes and clusters is also the namesake of the meeting: Health Sciences
At the recent networking event of the LBG, held on the twentieth floor of the Raiffeisenhaus in Vienna, Dr. Moriggl presented science minister Karlheinz Töchterle and President Josef Pröll with a collection of scientific images. He used the opportunity to show his gratitude to both for their support in extending the LBI-CR for a second funding period and discussed his future plans to maintain momentum for the research institute.
Scientists from the Ludwig Boltzmann Institut for Cancer Research have contributed to identify higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for “Rearranged during transfection”, are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.
A new stand alone project was accepted for funding at the board meeting of the Austrian Science Fund on June 25, 2013.
At the 4th Annual Meeting of the European Research Initiative on ALK-related Malignancies (ERIA) on June 27-28, 2013 Moriggl and Kenner joined an international group of leading scientists in leukemia research.
Professor Lukas Kenner of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) in Vienna receives the 2013 Research Award of the "Central European Society for Anticancer Drug Research" (CESAR).